Oral infliximab nanomedicines for targeted treatment of inflammatory bowel diseases.

Mohan, Lauren J; Daly, Jacqueline S; Ryan, Barbara M; Ramtoola, Zebunnissa

Mohan, Lauren J; Daly, Jacqueline S; Ryan, Barbara M; Ramtoola, Zebunnissa.

Afiliación

Mohan LJ; Division of Biology, Department of Anatomy and Regenerative Medicine, RCSI University of Medicine and Health Sciences, 2, Dublin, Ireland; School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, 2, Dublin, Ireland.
Daly JS; Division of Biology, Department of Anatomy and Regenerative Medicine, RCSI University of Medicine and Health Sciences, 2, Dublin, Ireland.
Ryan BM; Department of Gastroenterology and Clinical Medicine, Tallaght Hospital and Trinity College, Dublin, Ireland.
Ramtoola Z; School of Pharmacy and Biomolecular Sciences, RCSI University of Medicine and Health Sciences, 2, Dublin, Ireland. Electronic address: zramtoola@rcsi.ie.

Eur J Pharm Sci ; 183: 106379, 2023 Apr 01.

Article en En | MEDLINE | ID: mdl-36646154

Asunto(s)

Enfermedades Inflamatorias del Intestino; Nanopartículas; Humanos; Infliximab; Nanomedicina; Calidad de Vida; Inhibidores del Factor de Necrosis Tumoral; Mucosa Intestinal; Portadores de Fármacos

Palabras clave

Caco-2 cells; Inflammatory bowel disease; Infliximab; Nanoparticles; Oral targeted delivery; PLGA-PEG

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Enfermedades Inflamatorias del Intestino / Nanopartículas Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Eur J Pharm Sci Asunto de la revista: FARMACIA / FARMACOLOGIA / QUIMICA Año: 2023 Tipo del documento: Article País de afiliación: Irlanda

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google